Par-4 inducible apoptosis in prostate cancer cells

Journal of Cellular Biochemistry

Volumn 91, Issue 3, 2004, Pages 504-512

  Gurumurthy, Sushma ^a   Rangnekar, Vivek M ^a,b,c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Apoptosis; Par 4; Prostate

Indexed keywords

5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; ANDROGEN; ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; FAS ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MACROGOL; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NIMESULIDE; PROSTATE APOPTOSIS RESPONSE 4; PROTEIN KINASE C; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; CARRIER PROTEIN; PROSTATE APOPTOSIS RESPONSE 4 PROTEIN; PROSTATE APOPTOSIS RESPONSE-4 PROTEIN; SIGNAL PEPTIDE;

APOPTOSIS; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL DEATH; CELL PROLIFERATION; COLON CANCER; DRUG ACTIVITY; ENZYME ACTIVITY; EPITHELIUM CELL; HUMAN; LEUKOCYTE MIGRATION INHIBITION TEST; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR REGRESSION; ANIMAL; CELL TRANSFORMATION; GENE EXPRESSION REGULATION; GENETICS; MALE; MOUSE; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR;

ANIMALIA;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARRIER PROTEINS; CELL DEATH; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; PROSTATIC NEOPLASMS;

EID: 3843127864     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.20000     Document Type: Review

References (36)

1. Barradas M, Monjas A, Diaz-Meco MT, Serrano M, Moscat J. 1999. The downregulation of the pro-apoptotic protein Par-4 is critical for Ras-induced survival and tumor progression. EMBO J 18:6362-6369.
2. Boehrer S, Chow KU, Puccetti E, Ruthardt M, Godzisard S, Krapohl A, Schneider B, Hoelzer D, Mitrou PS, Rangnekar VM, Weidmann E. 2001. Deregulated expression of prostate apoptosis response gene-4 in less differentiated lymphocytes and inverse expressional patterns of par-4 and bcl-2 in acute lymphocytic leukemia. 2:103-107.
3. Boehrer S, Chow KU, Beske F, Kukoc-Zivojnov N, Puccetti E, Ruthardt M, Baum C, Rangnekar VM, Hoelzer D, Mitrou PS, Weidmann E. 2002. In lymphatic cells par-4 sensitizes to apoptosis by down-regulating bcl-2 and promoting disruption of mitochondrial membrane potential and caspase activation. Cancer Res 62:1768-1775.
4. Boghaert ER, Sells SF, Walid AJ, Malone P, Williams NM, Weinstein MH, Strange R, Rangnekar VM. 1997. Immunohistochemical analysis of the proapoptotic protein Par-4 in normal rat tissues. Cell Growth Differ 8:881-890.
5. Bruckheimer EM, Gjertsen BT, McDonnell TJ. 1999. Implications of cell death regulation in the pathogenesis and treatment of prostate cancer. Semin Oncol 26:382-398.
6. Chakraborty M, Qiu SG, Vasudevan KM, Rangnekar VM. 2001. Par-4 drives trafficking and activation of Fas and Fasl to induce prostate cancer cell apoptosis and tumor regression. Cancer Res 61:7255-7263.
7. Chang S, Kim JH, Shin J. 2002. P62 forms a ternary complex with PKCzeta and PAR-4 and antagonizes PAR-4-induced PKCzeta inhibition. FEBS Lett 510:57-61.
8. Cheema SK, Mishra SK, Rangnekar VM, Tari AM, Kumar R, Lopez-Berestein G. 2003. Par-4 transcriptionally regulates Bcl-2 through a WT1-binding site on the bcl-2 promoter. J Biol Chem 278:19995-20005.
9. Cook J, Krishnan S, Ananth S, Sells SF, Shi Y, Walther MM, Linehan WM, Sukhatme VP, Weinstein MH, Rangnekar VM. 1999. Decreased expression of the proapoptotic protein Par-4 in renal cell carcinoma. Oncogene 18:1205-1208.
10. Corpet DE, Parnaud G, Delverdier M, Peiffer G, Tache S. 2000. Consistent and fast inhibition of colon carcinogenesis by polyethylene glycol in mice and rats given various carcinogens. Cancer Res 60:3160-3164.
11. de Thonel A, Bettaieb A, Jean C, Laurent G, Quillet-Mary A. 2001. Role of protein kinase C zeta isoform in Fas resistance of immature myeloid KG1a leukemic cells. Blood 98:3770-3777.
12. Diaz-Meco MT, Municio MM, Frutos S, Sanchez P, Lozano J, Sanz L, Moscat J. 1996. The product of par-4, a gene induced during apoptosis, interacts selectively with the atypical isoforms of protein kinase C. Cell 86:777-786.
13. Diaz-Meco MT, Lallena MJ, Monjas A, Frutos S, Moscat J. 1999. Inactivation of the inhibitory kappaB protein kinase/nuclear factor kappaB pathway by Par-4 expression potentiates tumor necrosis factor alpha-induced apoptosis. J Biol Chem 274:19606-19618.
14. El-Guendy N, Zhao Y, Gurumurthy S, Burikhanov R, Rangnekar VM. 2003. Identification of a unique core domain of par-4 sufficient for selective apoptosis induction in cancer cells. Mol Cell Biol 23:5516-5525.
15. Garcia-Cao I, Lafuente MJ, Criado LM, Diaz-Meco MT, Serrano M, Moscat J. 2003. Genetic inactivation of Par4 results in hyperactivation of NF-kappaB and impairment of JNK and p38. EMBO Rep 4:307-312.
16. Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell 100:57-70.
17. Herman JR, Gurumurthy S, Chakraborty M, Rangnekar VM. 2001. Par-4 causes regression of orthotopic tumors in immunocompetent mouse prostate cancer model: American Association for Cancer Research. Naples, FL.
18. Johnstone RW, See RH, Sells SF, Wang J, Muthukkumar S, Englert C, Haber DA, Licht JD, Sugrue SP, Roberts T, Rangnekar VM, Shi Y. 1996. A novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1. Mol Cell Biol 16:6945-6956.
19. Kalgutkar AS, Zhao Z. 2001. Discovery and design of selective cyclooxygenase-2 inhibitors as non-ulcerogenic, anti-inflammatory drugs with potential utility as anti-cancer agents. Curr Drug Targets 2:79-106.
20. Kawai T, Akira S, Reed JC. 2003. ZIP kinase triggers apoptosis from nuclear PML oncogenic domains. Mol Cell Biol 23:6174-6186.
21. Kimura M, Furukawa T, Abe T, Yatsuoka T, Youssef EM, Yokoyama T, Ouyang H, Ohnishi Y, Sunamura M, Kobari M, Matsuno S, Horii A. 1998. Identification of two common regions of allelic loss in chromosome arm 12q in human pancreatic cancer. Cancer Res 58:2456-2460.
22. Kogel D, Reimertz C, Mech P, Poppe M, Fruhwald MC, Engemann H, Scheidtmann KH, Prehn JH. 2001. Dlk/ZIP kinase-induced apoptosis in human medulloblastoma cells: Requirement of the mitochondrial apoptosis pathway. Br J Cancer 85:1801-1808.
23. Lafuente MJ, Martin P, Garcia-Cao I, Diaz-Meco MT, Serrano M, Moscat J. 2003. Regulation of mature T lymphocyte proliferation and differentiation by Par-4. EMBO J 22:4689-4698.
24. Lucas T, Pratscher B, Krishnan S, Fink D, Gunsberg P, Wolschek M, Wacheck V, Muster T, Romirer I, Wolff K, Pehamberger H, Eichler HG, Rangnekar VM, Jansen B. 2001. Differential expression levels of Par-4 in melanoma. Melanoma Res 11:379-383.
25. Nalca A, Qiu SG, El-Guendy N, Krishnan S, Rangnekar VM. 1999. Oncogenic Ras sensitizes cells to apoptosis by Par-4. J Biol Chem 274:29976-29983.
26. Page G, Kogel D, Rangnekar V, Scheidtmann KH. 1999. Interaction partners of Dlk/ZIP kinase: Co-expression of Dlk/ZIP kinase and Par-4 results in cytoplasmic retention and apoptosis. Oncogene 18:7265-7273.
27. Qiu G, Ahmed M, Sells SF, Mohiuddin M, Weinstein MH, Rangnekar VM. 1999a. Mutually exclusive expression patterns of Bcl-2 and Par-4 in human prostate tumors consistent with down-regulation of Bcl-2 by Par-4. Oncogene 18:623-631.
28. Qiu SG, Krishnan S, el-Guendy N, Rangnekar VM. 1999b. Negative regulation of Par-4 by oncogenic Ras is essential for cellular transformation. Oncogene 18:7115-7123.
29. Reed JC, Miyashita T, Krajewski S, Takayama S, Aime-Sempe C, Kitada S, Sato T, Wang HG, Harigai M, Hanada M, Krajewska M, Kochel K, Millan J, Kobayashi H. 1996. Bcl-2 family proteins and the regulation of programmed cell death in leukemia and lymphoma. Cancer Treat Res 84:31-72.
30. Roussigne M, Cayrol C, Clouaire T, Amalric F, Girard JP. 2003. THAP1 is a nuclear proapoptotic factor that links prostate-apoptosis-response-4 (Par-4) to PML nuclear bodies. Oncogene 22:2432-2442.
31. Sanz-Navares E, Fernandez N, Kazanietz MG, Rotenberg SA. 2001. Atypical protein kinase Czeta suppresses migration of mouse melanoma cells. Cell Growth Differ 12:517-524.
32. Schneider BG, Rha SY, Chung HC, Bravo JC, Mera R, Torres JC, Plaisance KT, Jr., Schlegel R, McBride CM, Reveles XT, Leach RJ. 2003. Regions of allelic imbalance in the distal portion of chromosome 12q in gastric cancer. Mol Pathol 56:141-149.
33. Sells SF, Wood DP, Jr., Joshi-Barve SS, Muthukumar S, Jacob RJ, Crist SA, Humphreys S, Rangnekar VM. 1994. Commonality of the gene programs induced by effectors of apoptosis in androgen-dependent and-independent prostate cells. Cell Growth Differ 5:457-466.
34. Sells SF, Han SS, Muthukkumar S, Maddiwar N, Johnstone R, Boghaert E, Gillis D, Liu G, Nair P, Monnig S, Collini P, Mattson MP, Sukhatme VP, Zimmer SG, Wood DP, Jr., McRoberts JW, Shi Y, Rangnekar VM. 1997. Expression and function of the leucine zipper protein Par-4 in apoptosis. Mol Cell Biol 17:3823-3832.
35. Yang E, Korsmeyer SJ. 1996. Molecular thanatopsis: A discourse on the BCL2 family and cell death. Blood 88:386-401.
36. Zhang Z, DuBois RN. 2000. Par-4, a proapoptotic gene, is regulated by NSAIDs in human colon carcinoma cells. Gastroenterology 118:1012-1017.